
|Videos|June 10, 2021
What To Know About Aducanumab and Slowing the Progression of Alzheimer Disease
Pharmacy Times spoke to Dr. Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.
Advertisement
Pharmacy Times spoke to Dr.Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Building the pharmacy of the future — trust, loyalty, and growth
2
Beyond the Transplant Center: IV Therapy in the Community
3
Understanding Axatilimab's Mechanism in the Context of Multiple Lines of Therapy
4
Incorporating Patient-Reported Symptoms into Treatment Plans
5


































































































